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OBJECTIVE: Heart failure (HF) is a leading cause of
hospitalization. Clinical and socio-demographic factors
have been associated with cardiac admissions, but little
i sk n o w na b o u tt h er o l eo fa n x i e t y .W ee x a m i n e d
whether symptoms of anxiety were associated with
cardiac hospitalizations at 12 months in HF patients.
METHODS: HF outpatients (N=237) completed the
Hospital Anxiety and Depression Scale (HADS) at
baseline (i.e., inclusion into the study). A cutoff ≥8
was used to indicate probable clinical levels of anxiety
and depression. At 12 months, a medical chart abstrac-
tion was performed to obtain information on cardiac
hospitalizations.
RESULTS: The prevalence of symptoms of anxiety was
24.9% (59/237), and 27.0% (64/237) of patients were
admitted for cardiac reasons at least once during the
12-month follow-up period. Symptoms of anxiety were
neither significantly associated with cardiac hospitali-
zations in univariable logistic analysis [OR=1.13, 95%
CI (0.59–2.17), p=0.72] nor in multivariable analysis
[OR=0.94, 95% CI (0.38–2.31), p=0.89]. New York Heart
Association (NYHA) functional class III [OR=3.00, 95%
CI (1.08–8.12), p=0.04] and a history of HF-related
hospitalizations [OR=1.18, 95% CI (1.01–1.38), p=0.03]
were independently associated with 12-month cardiac
admissions.
CONCLUSIONS: The current study found no significant
association between symptoms of anxiety and cardiac
hospitalizations at 12 months in HF patients. In
contrast, clinical indicators (i.e., NYHA class III and a
history of HF-related hospitalizations) were significantly
associated with admissions due to a cardiac cause.
Future studies are warranted to investigate the impor-
tance of symptoms of anxiety in HF using a larger
sample size and a longer follow-up duration.
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INTRODUCTION
Heart failure (HF) is considered the end stage of most heart
diseases,
1,2a n di sac h r o n i ca n dpr o g r e s s i v ec on d i t i o n .
3Currently,
HF is a leading cause of hospitalization, especially in patients
65 years or older.
4 In order to decrease morbidity, mortality, and
health-care costs, and to improve quality of life, a growing body of
literature has focused on the identification of patients at high risk
for hospitalizations for HF. Clinical, demographic, socioeconomic,
and psychological factors have been established as important
associates of hospitalizations among HF patients.
5,6
Most studies on the role of psychological factors in HF have
focused on depression,
7 with several studies indicating that
symptoms of depression are related to increased cardiovascular
mortality and morbidity,
8–10 including cardiac hospitalizations.
11–
13 Although symptoms of anxiety are commonly observed in HF,
14
only a paucity of studies have examined the association between
symptoms of anxiety and clinical outcomes,
7,15 with these results
being conflicting.
3 In some studies, symptoms of anxiety were not
associated with cardiac events,
12,16 mortality,
10,14,17 or cardiac
hospitalizations,
13,14,16 while other studies in HF patients showed
that anxiety was associated with higher rates of cardiac
events
18,19 and cardiac admissions.
12,20,21
Given this gap in knowledge on the role of anxiety and the
preliminary associations between anxiety and HF outcomes still
being inconclusive, we examined whether symptoms of anxiety
were associated with 12-month cardiac hospitalizations in HF
patients.
METHODS
Participants and Procedure
The total sample comprised 381 consecutive HF outpatients
recruited between June 2006 and December 2008 from the
outpatient clinics of two teaching hospitals (St. Elisabeth
Hospital, Tilburg, and Amphia Hospital, Breda, The Nether-
lands). All patients were treated according to the most recent
European Guidelines on HF.
22
Inclusion criteria were (1) diagnosis of HF, (2) left ventricular
ejection fraction (LVEF) ≤40%, (3) New York Heart Association
(NYHA) functional class I-III, and (4) stable on oral medication 1
month prior to inclusion. Patients were excluded from participa-
tion in case of age ≥80 years, myocardial infarction 1 month prior
to inclusion, hospital admissions 1 month prior to inclusion,
insufficient understanding of the Dutch language, other life-
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Springerlink.comthreatening diseases (e.g., cancer), cognitive impairments, and
presence of a chronic severe psychiatric condition (e.g., psychosis).
At baseline (i.e., inclusion into the study), HF patients were
asked to complete a self-report questionnaire to assess symp-
toms of anxiety and depression, and purpose-designed ques-
tionnaires were administered to collect data on patients’ socio-
demographics. Clinical characteristics were obtained at baseline
frompatients’medicalrecords,and at12months a medicalchart
abstraction was performed to obtain information about cardiac
hospitalizations between baseline and 12 months follow-up.
The study protocol was approved by the medical ethics
committees of the participating hospitals, and the study was
conducted according to the Helsinki declaration.
23 Patient
participation was voluntary, with patients being able to with-
draw from the study at any moment, without this decision
having implications for future medical treatment. Every patient
provided written informed consent.
Measures
Demographics, Clinical Characteristics, and Treatment
Variables. Socio-demographic variables included gender, age,
marital status (having a partner vs not having a partner),
educational level (secondary education and higher vs primary
education), and employment status (working vs not working).
Clinical variables were obtained from patients’ medical records
and included LVEF, NYHA class (NYHA class I/II vs NYHA class
III), body mass index (BMI), etiology (ischemic etiology vs
non-ischemic etiology), cardiac history [i.e., previous
myocardial infarction (MI), coronary artery bypass graft
surgery (CABG), or percutaneous coronary intervention (PCI)],
cerebrovascular history [cerebrovascular accident (CVA) or
transient ischemic attack (TIA)], co-morbidities (i.e., diabetes,
renal disease, liver disease, chronic obstructive pulmonary
disease (COPD), peripheral arterial disease (PAD), or
gastrointestinal comorbidities), risk factors (i.e., hypertension
or hypercholesterolemia), time since HF diagnosis in years,
previous HF hospitalizations, and self-reported smoking
(smoking vs not smoking). In addition, treatment variables
were collected and included participation in cardiac
rehabilitation, device therapy [i.e., pacemaker, biventricular
pacemaker, or implantable cardioverter defibrillator (ICD)],
and prescribed medications [i.e., ACE-inhibitors, angiotensin
II receptor antagonist (ARB), diuretics, digoxin, beta-blockers,
nitrates, calcium-antagonists, oral anticoagulants, aspirin,
statins, antidepressants, hypnotics, or anxiolytics].
Symptoms of Anxiety and Depression. Patients filled out the
Dutch version of the Hospital Anxiety and Depression Scale
(HADS) to assess symptoms of anxiety and depression.
24,25
Both subscales consist of seven items that are answered on a
four-point Likert scale ranging from 0 to 3.
24 A cutoff score of
≥8 on each subscale represents clinically relevant levels of
anxiety and depression.
26 The HADS has been demonstrated
to be a valid screening tool for detecting symptoms of anxiety
and depression in HF.
27 The internal consistency has been
demonstrated previously with Cronbach’s alpha of 0.83 for the
anxiety subscale and 0.82 for the depression subscale,
respectively.
26 In the current study, the correlation between
both subscales was 0.56, and Cronbach’s alphas were 0.84 for
HADS-A and 0.81 for HADS-D, respectively.
Endpoint. The endpoint was defined as cardiac hospitalizations
at 12 months, as documented in the patients’ medical records.
Hospitalization was defined as any planned or unplanned
overnight stay in the cardiology clinic of the two participating
hospitals. These cardiac hospitalizations comprised HF-related
admissions (e.g., HF aggravation) as well as cardiac
admissions not directly related to HF [e.g., myocardial
infarction (MI)]. Furthermore, cardiac day treatments that
required an overnight stay in the cardiology clinic (e.g.,
coronary angiography or cardioversion) were recorded as
cardiac hospitalizations as well. Events were not adjudicated.
However, the cause of hospitalization had to be documented by
the medical specialists in the patients’ medical records.
Statistical Analyses. Group differences were examined using
the chi-square test for dichotomous variables and Student’st -
test for independent samples for continuous variables. Logistic
regression analysis was conducted to determine whether
symptoms of anxiety were associated with 12-month cardiac
hospitalizations. Covariates were entered into the model using
the Enter method, thereby reducing the risk of overfitting.
28 In
multivariable analysis, we adjusted for symptoms of
depression (cutoff≥8), gender, cardiac history, and NYHA
class (I/II versus III), LVEF, and history of HF-related
hospitalizations. All covariates were selected a priori based on
the literature.
12,16,28–30 Odds ratios (OR) with their corresponding
Figure 1. Flow chart of patient selection.
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on two-tailed tests, and a p-value<0.05 was used to indicate
statistical significance. All statistical analyses were performed
using SPSS for Windows 17.0 (SPSS Inc., Chicago, IL).
RESULTS
Patient Characteristics
Of 381 patients, 121 initially refused participation (68.2%
response rate). Due to death prior to completion of the baseline
questionnaire,thequestionnairenotbeingreturned,orexclusion
due to missings on the questionnaire, final analyses were based
on data from 237 patients. A flow chart of the patient selection is
provided in Figure 1. No systematic differences between partici-
pants and non-participants were found except for non-partici-
pants more often being classified in NYHA III compared with
participants [31.6% vs 9.3%; X
2(1)=6.81, p=0.01).
T h ep r e v a l e n c eo fs y m p t o m so f anxiety was 24.9% (59/237).
Moreover, 27.0% (64/237) of patients were admitted for cardiac
reasons at least once during the 12-month follow-up period.
Patient characteristics stratified by symptoms of anxiety are
presentedinTable1.Somesignificantdifferencesemergedbetween
anxious and non-anxious HF patients, with anxious patients more
often being female, prescribed nitrates and hypnotics, having a
cardiac history, having a job, and experiencing symptoms of
depression, compared with non-anxious patients (all ps<0.05).
Symptoms of Anxiety and Cardiac Hospitalizations
at 12 Months
Figure 2 displays cardiac hospitalizations at 12 months strat-
ified by symptoms of anxiety. In univariable logistic regression
analysis, symptoms of anxiety were not significantly associated
with increased cardiac hospitalizations at 12 months [OR=
1.13, 95% CI (0.59–2.17), p=0.72].
Table 1. Patient Characteristics Stratified by Symptoms of Anxiety*
Total
sample (N=237)
Symptoms of anxiety
(i.e., HADS-A≥8) (n=59)
No symptoms of anxiety
(i.e., HADS-A≤7) (n=178)
p
Demographics
Women 51 (21.5) 20 (33.9) 31 (17.4) 0.01
∥
Age, mean (SD) 66.9 (8.7) 68.8 (8.5) 66.3 (8.7) 0.05
Having a partner 183 (77.2) 44 (74.6) 139 (78.1) 0.71
Secondary education and higher 91 (39.1) 19 (32.2) 72 (41.4) 0.27
Having a job 33 (13.9) 3 (5.1) 30 (16.9) 0.04
∥
Clinical variables
BMI, mean (SD) 28.2 (5.2) 28.7 (5.0) 28.0 (5.3) 0.36
Self-reported smoking 55 (23.5) 16 (27.1) 39 (22.3) 0.56
NYHA functional class I/II 205 (90.7) 50 (84.7) 155 (92.8) 0.12
LVEF, mean (SD) 33.6 (6.7) 34.6 (5.6) 33.2 (7.1) 0.14
Time since diagnosis in years, mean (SD) 5.0 (4.6) 5.7 (5.5) 4.8 (4.3) 0.28
Ischemic etiology 155 (65.4) 42 (71.2) 113 (63.5) 0.36
Cardiac history
† 165 (69.6) 48 (81.4) 117 (65.7) 0.04
∥
Cerebrovascular history
‡ 30 (12.7) 8 (13.6) 22 (12.4) 1.00
Diabetes mellitus 70 (29.5) 21 (35.6) 49 (27.5) 0.31
Renal disease 17 (7.2) 6 (10.2) 11 (6.2) 0.46
COPD 48 (20.3) 15 (25.4) 33 (18.5) 0.34
PAD 29 (12.2) 9 (15.3) 20 (11.2) 0.56
Hypertension 120 (50.6) 26 (44.1) 94 (52.8) 0.31
Hypercholesterolemia 163 (68.8) 43 (72.9) 120 (67.4) 0.53
History of HF-related hospitalizations, mean (SD) 1.5 (2.0) 1.7 (1.9) 1.4 (2.1) 0.35
Symptoms of depression (i.e., HADS-D≥8) 65 (27.4) 42 (71.2) 23 (12.9) <0.001
∥
Treatment variables
Cardiac rehabilitation 24 (10.4) 6 (10.3) 18 (10.4) 1.00
Device therapy
§ 32 (13.5) 10 (16.9) 22 (12.4) 0.50
ACE-inhibitor 140 (59.1) 34 (57.6) 106 (59.6) 0.91
ARB 76 (32.1) 18 (30.53) 58 (32.6) 0.89
Diuretics 152 (64.1) 41 (69.5) 111 (62.4) 0.41
Digoxin 39 (16.5) 11 (18.6) 28 (15.7) 0.75
Beta-blocker 162 (68.4) 40 (67.8) 122 (68.5) 1.00
Nitrates 92 (38.8) 30 (50.8) 62 (34.8) 0.04
∥
Calcium-antagonist 35 (14.8) 12 (20.3) 23 (12.9) 0.24
Oral anti-coagulants 147 (62.9) 35 (59.3) 112 (62.9) 0.74
Aspirin 86 (36.3) 23 (39.0) 63 (35.4) 0.73
Statins 168 (70.9) 43 (72.9) 125 (70.20) 0.82
Hypnotics 17 (7.2) 11 (18.64) 6 (3.4) <0.001
∥
Anxiolytics 15 (6.3) 7 (11.9) 8 (4.5) 0.09
*Results are presented as n (%) unless otherwise stated
†Myocardial infarction (MI), percutaneous coronary intervention (PCI) or coronary artery bypass graft surgery (CABG)
‡Cerebrovascular accident (CVA) or transient ischemic attack (TIA)
§Either single, biventricular, or implantable cardioverter device (ICD)
∥p<.05
Abbreviations: ARB = angiotensin II receptor blockers; BMI = body mass index (kg/m
2); COPD = chronic obstructive pulmonary disease; LVEF = left
ventricular ejection fraction; NYHA = New York Heart Association functional class; PAD = peripheral arterial disease
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independently associated with cardiac hospitalizations at
12 months (Table 2), while NYHA functional class III [OR=3.00,
9 5 %C I( 1 . 0 8 –8.12), p=0.04] and a history of HF-related
hospitalizations [OR=1.18, 95% (1.01–1.38), p=0.03] were relat-
ed to increased cardiac hospitalizations. Secondary analysis, in
which continuous anxiety scores were examined as possible
associates of cardiac hospitalizations, yielded similar results.
DISCUSSION
Heart failure (HF) is a leading cause of hospitalization. Clinical
and socio-demographic factors have been associated with
cardiac admissions, but little is known about the role of
anxiety. Results of the current study demonstrated that
symptoms of anxiety were not independently associated with
12-month cardiac hospitalizations. However, patients with a
higher NYHA class and a history of HF-related hospitalizations
were at 3-fold and 1.5-fold increased odds for hospital admis-
sions due to a cardiac cause, respectively.
In the current study, the prevalence of symptoms of anxiety
of 24.9% was relatively low compared with previous studies
reporting rates of 28–56% in HF.
13,18,19,21 However, previous
studies mainly used the Spielberger State-Trait Anxiety Inven-
tory (STAI) to assess symptoms of anxiety (e.g.,
13,18), which
hampers comparability with the current study as we used the
HADS. The proportion of patients that was admitted due to
a cardiac cause at least once (26.9%) is in line with findings
from previous studies, reporting rates between 22% and
28%.
12,16,20,21
The results of the current study are in line with previous
studies, demonstrating that symptoms of anxiety were not
significantly associated with cardiac hospitalizations in cardi-
ac patients.
13,14,16 Although other studies demonstrated that
symptoms of anxiety were associated with hospitaliza-
tions
12,20,21 the current study did not corroborate these
findings. However, these discrepancies may be explained by
smaller or different sample sizes (i.e., 65 HF outpatients, 111
HF outpatients, and 139 HF outpatients, respectively) and the
assessment of symptoms of anxiety using other instruments
than the HADS.
In the current study, symptoms of depression were not
significantly associated with cardiac hospitalizations at
12 months. This finding is in contrast with previous studies,
demonstrating that symptoms of depression were significantly
associated with clinical outcomes in HF, including admissions
for cardiac reasons,
11–13 and cardiovascular morbidity and
mortality.
8–10 These discrepancies may possibly be attributed
to the instruments used to assess symptoms of depression or
differences in the follow-up duration. In the current study,
symptoms of depression were assessed with the HADS,
whereas previous studies mainly used the Beck Depression
Inventory (BDI) (e.g.,
8,10,13) or the Center for Epidemiologic
Studies Depression scale (CES-D).
11
Clinical factors were the most important associates of
cardiac admissions in the current study. Higher NYHA func-
tional class and a history of HF-related hospitalizations were
independently associated with cardiac hospitalizations at
12 months. These results are consistent with the literature
on disease progression in HF, which describes that in the end
stages of cardiovascular disease, like HF, clinical indicators are
associated with poor prognosis (e.g.,
10,16). Hence, psycholog-
ical factors, like symptoms of anxiety, may be mainly impor-
tant in evaluating the burden of HF on patients, whereas in the
prediction of clinical deterioration (such as cardiac hospitali-
zations) psychological factors may play less of a role.
17
Following this line of thought, it is possible that symptoms
of anxiety may be associated with clinical outcomes in earlier
stages of cardiovascular disease rather than in HF. Previous
studies support this notion, showing that symptoms of anxiety
are associated with higher rates of recurrent coronary events,
cardiac hospitalizations, and cardiac mortality in patients
admitted for elective CABG or valve surgery,
31 post-MI
patients,
32 and ICD patients.
33 In addition, anxiety symptoms
have been linked with poor patient-centered outcomes in HF,
such as impaired health-related quality of life.
34,35 Although
symptoms of anxiety may not be associated with clinical HF
outcomes, patient-centered outcomes are important in their
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Figure 2. Proportion of cardiac hospitalizations at 12 months
stratified by symptoms of anxiety.
Table 2. Independent Associates of Cardiac Hospitalizations in HF
Patients at 12 Months*
OR 95% CI p
Symptoms of anxiety
(i.e., HADS-A≥8)
0.94 0.38–2.31 0.89
Female gender 0.46 0.19–1.11 0.09
Symptoms of depression
(i.e., HADS-D≥8)
1.22 0.52–2.84 0.65
Cardiac history
† 1.23 0.60–2.49 0.57
NYHA functional class III
‡ 3.00 1.08–8.12 0.04
∥
LVEF
§ 0.99 0.94–1.04 0.57
History of HF-related hospitalizations 1.18 1.01–1.38 0.03
∥
*Multivariable analysis
†Myocardial infarction (MI), percutaneous coronary interventions (PCI), or
coronary artery bypass graft surgery (CABG)
‡NYHA = New York Heart Association functional class
§LVEF = Left ventricular ejection fraction
∥p<.05
348 Damen et al.: Anxiety and Hospitalizations in HF JGIMown right,as they may serve as performance measures inclinical
practice to optimize clinical care
36 and have independent prog-
nostic value beyond demographic and clinical risk markers.
37
The findings of the current study should be interpreted with
some caution. First, subclinical symptoms of anxiety and
depression were assessed using self-report, and no information
on an established clinical diagnosis of anxiety was collected.
Second, since patients with more severe HF were not seen in the
outpatient clinic, the majority of patients included were classi-
fied as NYHA I/II, which hampers generalizability to the general
HF population and to patients with more severe HF in
particular. Third, information on hospitalizations was only
collected from the hospitals in which patients were enrolled in
the study, and adjudication was not included in the study
protocol. Hence, no information was available on cardiac
hospitalizations from other centers, which could have led to a
potential underestimation of the number of admissions. How-
ever, we also collected information on 12-month clinical events,
including cardiac hospitalizations, by means of a self-report
questionnaire. We compared information on these self-report
admissions with the information retrieved from patients’ med-
ical records, and overall, hospitalizations were comparable.
Fourth, the sample size of the current study was relatively
small, although comparable to previous studies in HF patients
(e.g.,
13,20,21). Nevertheless, power problems may have possibly
occurred and limit the generalizability of the findings. Strengths
of the study include its multicenter design, and the use of a
validated and reliable questionnaire that is frequently used in
patients with cardiovascular disease and HF.
38
Given that HF is a leading cause of hospitalizations,
4 it is
important to identify risk markers for hospitalizations in HF. To
date, only a paucity of studies has examined the association
between symptoms of anxiety and subsequent clinical outcomes
in HF,
7,15 with follow-up ranges mainly varying between 6 and
12 months.
10,12,20 In order to optimize clinical care, future
studies using a larger sample size and a longer follow-up
duration are warranted to more precisely investigate the
complex nature of anxiety as an associate of hospitalizations in
HF patients. Especially the co-occurrence of symptoms of
anxiety and depression should be considered in future research,
since these frequently go together
39 and have been associated
with impaired health outcomes.
17
In conclusion, symptoms of anxiety were not independently
associated with cardiac hospitalizations at 12 months in HF
patients. In contrast, clinical indicators of disease severity (i.e.,
higher NYHA functional class and a history of HF-related
hospitalizations) were significantly associated with increased
cardiac admissions. Future studies are warranted to examine
the influenceofanxiety in the contextof HFusinga larger sample
size and a longer follow-up duration than in the current study.
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